Clinical Trials at USC

1 Results for

Study Title	Principal Investigator
A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered With a Background-Regimen (BR) Containing a Ritonavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects Terminated \| Pediatric HIV \| Multisite View full trial information >>	Gilead Director

Study Title

Principal Investigator

Terminated | Pediatric HIV | Multisite

Gilead Director